

## LIDDS: NanoZolid® technology receives US patent valid until 2037

---

**The United States Patent and Trademark Office has issued a Notice of Allowance for the NanoZolid® technology patent. This will provide additional patent protection for all LIDDS development projects. The same patent was approved by the European Patent Office in 2018.**

This new patent protects fundamental parts of the production process for all types of NanoZolid® based formulations that LIDDS develops with the aim of out-licensing to the pharmaceutical industry.

With this new US patent, the NanoZolid® technology will be protected until 2037 in both Europe and in the US. LIDDS will pursue additional patent applications in all major markets to establish a worldwide patent extension.

- As the new patent substantially extends the patent protection of our NanoZolid® technology, it has a strong commercial upside in terms of prolonged partner agreements and royalty payments. This patent is of fundamental importance to LIDDS and to our future licencees, says Monica Wallter, CEO of LIDDS.

The patent referred to by the United States Patent and Trade Mark Office is the patent no. WO 2018073165 with the US application number 16/094,784, titled: "A new method for producing calcium sulfate hemihydrate with unique properties".

A Notice of Allowance is issued by the US Patent and Trademark Office after a patent examiner has decided to issue the requested patent and is the final step in the patent process.

**For more information, please contact:**

Monica Wallter, CEO, +46 (0)737 07 09 22, [monica.wallter@liddspharma.com](mailto:monica.wallter@liddspharma.com)

**LIDDS AB (publ)** is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, [Certifiedadviser@redeye.se](mailto:Certifiedadviser@redeye.se), +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit [www.liddspharma.com](http://www.liddspharma.com)